eligibility_summary
Eligibility: Female ≥18 with histologically confirmed ER+ (>1%) breast cancer, no neoadjuvant therapy, and cold-activated brown fat (Δtemp >1°C). Two cohorts (N=15 each): HER2+/ER+ set for adjuvant chemo + 17 trastuzumab series and endocrine therapy, HER2–/ER+ set for adjuvant chemo and endocrine therapy. Exclusions: other recent cancer, metastatic disease, diabetes (unless controlled), prednisolone use, pregnancy, uncontrolled HTN, arrhythmia, CAD/angina, HF (NYHA ≥2), cold urticaria.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational 1-year cohort comparing HER2+/ER+ breast cancer patients receiving standard trastuzumab vs HER2−/ER+ controls without HER2 blockade. Drug: trastuzumab—recombinant humanized IgG1 monoclonal antibody (anti-neoplastic) against HER2/ErbB2. Mechanism: binds HER2, prevents ErbB receptor dimerization/activation, downregulates ErbB signaling (PI3K/AKT/MAPK), promotes receptor internalization and ADCC in tumors. Study question: does systemic HER2 inhibition reduce brown adipose tissue (BAT) development/activity. Targets: HER2/ErbB2 on brown adipocytes and the ErbB pathway regulating BAT differentiation and thermogenesis (e.g., UCP1, lipid/glucose uptake).